Download PDF
Semin Neurol 2012; 32(03): 196-203
DOI: 10.1055/s-0032-1329195
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Diabetic Neuropathies: Practical and Rational Therapy

J. Robinson Singleton
1   University of Utah School of Medicine, Salt Lake City, Utah
2   Department of Neurology
,
A. Gordon Smith
1   University of Utah School of Medicine, Salt Lake City, Utah
3   Department of Neurology and Pathology
› Author Affiliations
Further Information

Publication History

Publication Date:
01 November 2012 (online)

   Permissions and Reprints

Abstract

Diabetes is associated with a variety of chronic and acute neuropathies. In this article, the authors summarize the clinical features of the most common diabetic neuropathies, focusing on those for which therapy is available or under active investigation. Distal symmetric polyneuropathy (DSP) is the most common form. Potential treatments for DSP are discussed in four broad themes: (1) medication and lifestyle therapy to improve hyperglycemia, insulin resistance, and attendant features of metabolic syndrome, including obesity and dyslipidemia; (2) pharmacologic therapy to alter neuropathy natural history aimed at rational targets from known pathophysiology; (3) symptomatic relief of neuropathic pain; and (4) treatment to prevent complications of neuropathy, including stasis ulcers and falls. The approach to the most common acute diabetic neuropathies is also reviewed.

Keywords

diabetes - peripheral neuropathy - diabetic amyotrophy
 

  • References

  • 1 Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47 (2) 123-128
    CrossrefPubMedGoogle Scholar
  • 2 Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 2001; 88 (1) 68-71
    CrossrefPubMedGoogle Scholar
  • 3 Zambelis T, Tsivgoulis G, Karandreas N. Carpal tunnel syndrome: associations between risk factors and laterality. Eur Neurol 2010; 63 (1) 43-47
    CrossrefPubMedGoogle Scholar
  • 4 Becker J, Nora DB, Gomes I , et al. An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome. Clin Neurophysiol 2002; 113 (9) 1429-1434
    CrossrefPubMedGoogle Scholar
  • 5 Thomsen NO, Cederlund R, Rosén I, Björk J, Dahlin LB. Clinical outcomes of surgical release among diabetic patients with carpal tunnel syndrome: prospective follow-up with matched controls. J Hand Surg Am 2009; 34 (7) 1177-1187
    CrossrefPubMedGoogle Scholar
  • 6 Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991; 48 (11) 1130-1135
    CrossrefPubMedGoogle Scholar
  • 7 Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJ. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus Neuropathy?. Ann Neurol 2011; 69 (6) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 8 Tracy JA, Engelstad JK, Dyck PJ. Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy. J Clin Neuromuscul Dis 2009; 11 (1) 44-48
    CrossrefPubMedGoogle Scholar
  • 9 Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med 2009; 10 (8) 1476-1480
    CrossrefPubMedGoogle Scholar
  • 10 Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2009; (3) CD006521
    PubMedGoogle Scholar
  • 11 Tesfaye S, Chaturvedi N, Eaton SE , et al; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352 (4) 341-350
    CrossrefPubMedGoogle Scholar
  • 12 Alberti KG, Eckel RH, Grundy SM , et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120 (16) 1640-1645
    CrossrefPubMedGoogle Scholar
  • 13 Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci 2008; 273 (1–2) 25-28
    CrossrefPubMedGoogle Scholar
  • 14 Tesfaye S, Selvarajah D. The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?. Curr Diab Rep 2009; 9 (6) 432-434
    CrossrefPubMedGoogle Scholar
  • 15 Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21 (3) 252-255
    CrossrefPubMedGoogle Scholar
  • 16 Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24 (9) 1225-1228
    CrossrefPubMedGoogle Scholar
  • 17 Skrapari I, Tentolouris N, Perrea D, Bakoyiannis C, Papazafiropoulou A, Katsilambros N. Baroreflex sensitivity in obesity: relationship with cardiac autonomic nervous system activity. Obesity (Silver Spring) 2007; 15 (7) 1685-1693
    CrossrefPubMedGoogle Scholar
  • 18 Hughes RA, Umapathi T, Gray IA , et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004; 127 (Pt 8) 1723-1730
    CrossrefPubMedGoogle Scholar
  • 19 Callaghan BC, Feldman E, Liu J , et al. Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Diabetes Care 2011; 34 (3) 635-640
    CrossrefPubMedGoogle Scholar
  • 20 Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58 (7) 1634-1640
    CrossrefPubMedGoogle Scholar
  • 21 Albers JW, Herman WH, Pop-Busui R , et al; Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33 (5) 1090-1096
    CrossrefPubMedGoogle Scholar
  • 22 Ismail-Beigi F, Craven T, Banerji MA , et al; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376 (9739) 419-430
    CrossrefPubMedGoogle Scholar
  • 23 Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543
    PubMedGoogle Scholar
  • 24 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348 (5) 383-393
    Google Scholar
  • 25 Balducci S, Iacobellis G, Parisi L , et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications 2006; 20 (4) 216-223
    CrossrefPubMedGoogle Scholar
  • 26 Kluding PM, Pasnoor M, Singh R , et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 2012; ; Epub ahead of print
    PubMedGoogle Scholar
  • 27 Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol 1997; 42 (5) 727-736
    CrossrefPubMedGoogle Scholar
  • 28 Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44 (12) 1355-1361
    CrossrefPubMedGoogle Scholar
  • 29 Kennedy JM, Zochodne DW. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage?. Diabetes 2005; 54 (3) 830-837
    CrossrefPubMedGoogle Scholar
  • 30 Russell JW, Berent-Spillson A, Vincent AM, Freimann CL, Sullivan KA, Feldman EL. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis 2008; 30 (3) 420-429
    CrossrefPubMedGoogle Scholar
  • 31 Obrosova IG, Drel VR, Oltman CL , et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab 2007; 293 (6) E1645-E1655
    CrossrefPubMedGoogle Scholar
  • 32 Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008; 14 (10) 953-961
    CrossrefPubMedGoogle Scholar
  • 33 Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58 (10) 2376-2385
    CrossrefPubMedGoogle Scholar
  • 34 Coppey LJ, Davidson EP, Rinehart TW , et al. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006; 55 (2) 341-348
    CrossrefPubMedGoogle Scholar
  • 35 Apfel SC, Schwartz S, Adornato BT , et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284 (17) 2215-2221
    CrossrefPubMedGoogle Scholar
  • 36 Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 2007; (4) CD004572
    PubMedGoogle Scholar
  • 37 Hotta N, Akanuma Y, Kawamori R , et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29 (7) 1538-1544
    CrossrefPubMedGoogle Scholar
  • 38 Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52 (12) 2867-2873
    CrossrefPubMedGoogle Scholar
  • 39 Ziegler D, Ametov A, Barinov A , et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29 (11) 2365-2370
    CrossrefPubMedGoogle Scholar
  • 40 Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21 (2) 114-121
    CrossrefPubMedGoogle Scholar
  • 41 Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28 (1) 89-94
    CrossrefPubMedGoogle Scholar
  • 42 Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116 (10) 600-605
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Apfel SC, Schwartz S, Adornato BT , et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284 (17) 2215-2221
    CrossrefPubMedGoogle Scholar
  • 44 Fink DJ, Wechuck J, Mata M , et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol 2011; 70 (2) 207-212
    CrossrefPubMedGoogle Scholar
  • 45 Ropper AH, Gorson KC, Gooch CL , et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009; 65 (4) 386-393
    CrossrefPubMedGoogle Scholar
  • 46 Dellon AL. Neurosurgical prevention of ulceration and amputation by decompression of lower extremity peripheral nerves in diabetic neuropathy: update 2006. Acta Neurochir Suppl (Wien) 2007; 100: 149-151
    CrossrefPubMedGoogle Scholar
  • 47 Weintraub MI, Wolfe GI, Barohn RA , et al; Magnetic Research Group. Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2003; 84 (5) 736-746
    CrossrefPubMedGoogle Scholar
  • 48 Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med 2010; 42 (4) 289-295
    PubMedGoogle Scholar
  • 49 Powell MW, Carnegie DH, Burke TJ. Reversal of diabetic peripheral neuropathy with phototherapy (MIRE) decreases falls and the fear of falling and improves activities of daily living in seniors. Age Ageing 2006; 35 (1) 11-16
    CrossrefPubMedGoogle Scholar
  • 50 Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev 2008; (3) CD006152
    PubMedGoogle Scholar
  • 51 Daousi C, Benbow SJ, Woodward A, MacFarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med 2006; 23 (9) 1021-1024
    CrossrefPubMedGoogle Scholar
  • 52 Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. Diabetes Care 2008; 31 (Suppl. 02) S255-S261
    CrossrefPubMedGoogle Scholar
  • 53 Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326 (19) 1250-1256
    CrossrefPubMedGoogle Scholar
  • 54 Backonja M, Beydoun A, Edwards KR , et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280 (21) 1831-1836
    CrossrefPubMedGoogle Scholar
  • 55 Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008; 8: 33
    CrossrefPubMedGoogle Scholar
  • 56 Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116 (1–2) 109-118
    CrossrefPubMedGoogle Scholar
  • 57 Tanenberg RJ, Irving GA, Risser RC , et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011; 86 (7) 615-626
    CrossrefPubMedGoogle Scholar
  • 58 Mittal M, Pasnoor M, Mummaneni RB , et al. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. Int J Neurosci 2011; 121 (9) 521-527
    CrossrefPubMedGoogle Scholar
  • 59 Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16 (2, Suppl) S49-S55
    CrossrefPubMedGoogle Scholar
  • 60 Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105 (1-2) 71-78
    CrossrefPubMedGoogle Scholar
  • 61 Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008; 12 (6) 804-813
    CrossrefPubMedGoogle Scholar
  • 62 Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 2010; 11 (5) 462-471
    CrossrefPubMedGoogle Scholar
  • 63 Schwartz S, Etropolski M, Shapiro DY , et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27 (1) 151-162
    CrossrefPubMedGoogle Scholar
  • 64 Harati Y, Gooch C, Swenson M , et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000; 14 (2) 65-70
    CrossrefPubMedGoogle Scholar
  • 65 Harati Y, Gooch C, Swenson M , et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50 (6) 1842-1846
    CrossrefPubMedGoogle Scholar
  • 66 Freeman R, Raskin P, Hewitt DJ , et al; CAPSS-237 Study Group. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007; 23 (1) 147-161
    CrossrefPubMedGoogle Scholar
  • 67 Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998; 56 (4) 691-707
    CrossrefPubMedGoogle Scholar
  • 68 Forst T, Pohlmann T, Kunt T , et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002; 39 (1) 1-6
    CrossrefPubMedGoogle Scholar
  • 69 Macgilchrist C, Paul L, Ellis BM, Howe TE, Kennon B, Godwin J. Lower-limb risk factors for falls in people with diabetes mellitus. Diabet Med 2010; 27 (2) 162-168
    CrossrefPubMedGoogle Scholar
  • 70 DeMott TK, Richardson JK, Thies SB, Ashton-Miller JA. Falls and gait characteristics among older persons with peripheral neuropathy. Am J Phys Med Rehabil 2007; 86 (2) 125-132
    CrossrefPubMedGoogle Scholar
  • 71 Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23 (5) 606-611
    CrossrefPubMedGoogle Scholar
  • 72 Ramsey SD, Newton K, Blough D , et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22 (3) 382-387
    CrossrefPubMedGoogle Scholar
  • 73 Gregg EW, Sorlie P, Paulose-Ram R , et al; 1999-2000 national health and nutrition examination survey. Prevalence of lower-extremity disease in the US adult population > = 40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27 (7) 1591-1597
    CrossrefPubMedGoogle Scholar
  • 74 Ndip A, Ebah L, Mbako A. Neuropathic diabetic foot ulcers - evidence-to-practice. Int J Gen Med 2012; 5: 129-134
    PubMedGoogle Scholar